...Uriel Oanunu; Noa Gross Even-Zohar; Shlomzion Aumann; Vladimir Vainstein; Alexander Gural; Moshe E. Gatt; Arnon Haran; Boaz Nachmias Introduction: The treatment protocols of adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) have evolved, with the advent of pediatric...

...Lili Pan; Yongzhi Zheng; Hao Zheng Introduction: Improved understanding of the prognostic biomarkers associated with childhood acute lymphoblastic leukemia (ALL) is needed for accurate risk group stratification. This study aimed to identify potential long non-coding RNA (lncRNA) markers...

...Qing Zhang; Yi Dong; Zhimin Zhai; Lili Tao; Qianshan Tao Introduction: Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T (CAR-T) cell are effective treatments for acute lymphoblastic leukemia (ALL). Various forms of intra- and extramedullary relapses have been reported...

.... 2024 ETV6/RUNX1 Allogeneic hematopoietic stem cell transplantation Measurable residual disease Acute lymphoblastic leukemia In pediatric B-acute lymphoblastic leukemia (ALL), the ETV6/RUNX1 rearrangement, t(12;21)(p13;q22), is the most common recurrent genetic abnormality and affects...

...Fausto A. Rios-Olais; Fernando Gil-Lopez; Analy Mora-Cañas; Roberta Demichelis-Gómez Introduction: Tumor lysis syndrome (TLS) occurs frequently during induction therapy for acute lymphoblastic leukemia (ALL). Patients are categorized into intermediate- or high-risk based on the lactate...

...Li Zhou; Zhe Shan; Jiangsha Fan Introduction: Acute lymphoblastic leukemia (ALL) is a common hematologic neoplastic disease. This study discussed the effect of extracellular vesicles (EVs) released from bone marrow mesenchymal stem cells (BMSCs) on ALL cells and the mechanism. Methods: BMSCs-EVs...

... and refractory acute lymphoblastic leukemia (ALL) than conventional chemotherapy. But, blinatumomab suppresses humoral immunity due to long-lasting B-cell depletion during and after the treatment. The development of PML involves cellular immunity and impairment of humoral immunity. Although few cases...

...) molecule, was evaluated in an expansion cohort of the phase 1b/2 study (NCT02412306) in Japanese adult ( n = 14) and pediatric ( n = 17) patients with relapsed/refractory Philadelphia-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). Materials and methods: Globally recommended...

... is very rare and mostly fatal. Treatment recommendations for such a complication are not yet established. Here, we report the dramatic recovery of HLH/MAS following tisagenlecleucel infusion in a young patient with relapsed acute lymphoblastic leukemia using etoposide phosphate (EP). We propose...

...Elena Parovichnikova; Vera Troitskaya; Andrey Sokolov; Olga Gavrilina; Zalina Akhmerzaeva; Larissa Kuzmina; Galina Kliasova; Julia Chabaeva; Sergey Kulikov; Sergey Bondarenko; Olga Baranova; Olga Samoilova; Kamil Kaplanov; Natalia Minaeva; Valeriy Savchenko; Russian Acute Lymphoblastic Leukemia...

...Firas El Chaer; Noa G. Holtzman; Edward A. Sausville; Jennie Y. Law; Seung Tae Lee; Vu H. Duong; Maria R. Baer; Rima Koka; Zeba N. Singh; Nancy M. Hardy; Ashkan Emadi Adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with conventional chemotherapy have...

...Boaz Nachmias; Adir Shaulov; Moshe E. Gatt; Michael Shapira; Alexander Gural The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge. In 2012, a protocol combining bortezomib, dexamethasone, asparaginase, doxorubicin, and vincristine...

...Ruham Alshiekh-Nasany; Dan Douer Introduction: Similar to pediatric regimens, multiple doses of L -asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults...

...Patrick W. Burke; Dan Douer The cure rate of acute lymphoblastic leukemia (ALL) in children is 80%, compared to less than half in adults. A major proportion of this cure rate drop occurs in adolescents and young adults (AYAs). The age range defining this population varies between studies...

... is a conventional agent for relapsed or refractory acute lymphoblastic leukemia (ALL). However, an effective combination with other drugs and a feasible dosage has not been identified. A retrospective study of 46 patients with relapsed or refractory ALL was conducted to determine the efficacy of mitoxantrone...

... the phenotypic signature of T cells present at diagnosis in 39 pediatric patients with acute lymphoblastic leukemia (ALL) treated within standardized ALL-BFM study protocols. Previously described age associations of lymphocyte subpopulations in the peripheral blood of healthy children were reproduced in leukemic...

... for immunophenotyping of this malignancy. Treatment regimens for precursor B-cell ALL are suitable for such cases. Precursor B cell Acute lymphoblastic leukemia Immunophenotype Surface immunoglobulin light chain B-cell acute lymphocytic leukemia (ALL) can be classified into precursor B- and mature B-cell...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2013 Acute lymphoblastic leukemia Molecular mechanism Bortezomib Acute lymphocytic leukemia (ALL) is a malignant disorder that originates from one single hematopoietic...

... could suggest increased expression of HERV-K in leukemic cells. To elucidate the role of endogenous retroviruses in leukemogenesis, studies were undertaken to assess env gene expression of HERV-K and HERV-W in childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Results...

... risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML). Case Report: A 33-year-old male XP patient was diagnosed with acute megakaryoblastic leukemia with a complex karyotype. He received standard induction chemotherapy with cytarabine and daunorubicin. After the first cycle...